Teva Pharmaceutical Industries Ltd.’s attempt to produce greater efficacy with the investigational multiple sclerosis drug laquinimod by testing higher doses has backfired. The company revealed Jan. 4 that it will discontinue higher doses of laquinimod in two ongoing clinical trials after eight non-fatal cardiovascular events occurred.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?